Life Science Group receives cleanroom grant in UK
Design and build | Medications
LSG has secured financial support from Medilink Midlands to help improve the development capacity of its CellShip product ~
Life Science Group (LSG), a UK provider of life science research and manufacturing solutions, has secured financial support from Medilink Midlands to help it develop its CellShip ~ product.
CellShip ~ is a medium that allows cells to be transported without the need for dry ice, or for the cells to be fully frozen and stored in liquid nitrogen with all the transport problems that this produces.
Part of the grant will go to the development of a GMP / GLP clean room
Medilink Midlands innovation advisors worked with Life Science Group to secure an SNG grant for the company to attend an online cell culture conference (Best-of Biotherapeutics Analytical Summit: Cell & Gene Therapy Analytics) and recently obtained approval for a ~ 57,000 ACTIS ISG project funded by a GMP / GLP Cleanroom Development Grant. This will allow the company to further research and develop its innovative CellShip ~ product.
Funding for the ISG and SNG grants has been provided under the Medilink Midlands ACTIS program, which is partly funded by the European Regional Development Fund (ERDF).
Jenny Murray, Managing Director of Life Science Group, said: “We are grateful to Medilink Midlands for helping us secure grants, without it we could not complete our development to take advantage of an opportunity for CellShip ~ at spring 2022. “
Murray explained, “The conventional method of sending cells from A to B around the world is to mail frozen samples in several kilograms of dry ice. From storage to delivery, the cost is high and the procedure dangerous, with many couriers refusing to take cargo on dry ice. Transit delays are common (eg, slow customs inspection), and when this happens, dry ice often evaporates, leaving cells at risk for damage. In addition, cells are usually bathed in a cryoprotectant (10% DMSO), which is cytotoxic. “
Murray added, “While cell culture facilities will most likely continue to use this shipping method because their collections are stored in liquid nitrogen, other methods are being explored to minimize these frustrations and maximize. recovery of cells after transit. There is therefore a need. for a simple, inexpensive and safe method of transporting cell cultures between collaborators, researchers and healthcare professionals, especially when tailored cell lines become essential to maintaining health. CellShip ~ allows cells to be transported without the need for dry ice or for cells to be fully frozen and stored in liquid nitrogen with all the transport problems that this entails. “
LSG is now in the final stages of development of its innovative cell support medium, but has yet to perform final testing and examine the regulatory landscape to manufacture this product.
During COVID, LSG encountered serious problems accessing laboratories capable of providing end-stage testing assistance for regulatory approval of cell line solutions and carrier products. Research funding will help develop this unique product for the market using its own laboratories.
As a member of Medilink Midlands, the company also received a 15% discount on marketing support through Agora Marketing Communications. This has allowed the Life Science Group to proactively plan for the future and begin implementing a number of marketing initiatives to raise awareness of CellShip ~, its other products and services, and the company itself.